drugset / Trial / NCT06325566

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

NCT06325566

Phase 3 Active not recruiting 300 enrolled Mesoblast, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.

Timeline

Start
2024-07-03
Primary completion
2027-07
Completion
2028-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rexlemestrocel-L Cell therapy 6e+06 cells Other
Background Hyaluronic Acid Other / unclassified 1 ml Other